OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the
Group")
Directorate change
OptiBiotix Health plc ("OptiBiotix") announces
that Graham Myers, Finance Director of the Company, has notified
the Company that he will step down from the Board on 30 November
2024.
David Blain will join the Company as acting
Finance Director on 1 November 2024. Mr Blain's appointment to the
Board of the Company will be subject to normal regulatory due
diligence.
David is a member of ICAEW and has extensive
financial, commercial and Board experience in a number of private
and public companies, including Iksuda Therapeutics Ltd, Applied
Graphene Materials plc, Nanoco Group plc and Inspired Capital plc
(formerly Renovo Group plc). Mr Blain is currently Financial
Director (non-board position) at Iksuda Therapeutics
Ltd.
The Company notes recent speculation in
relation to the health of the Company's Chief Executive Officer
Stephen O'Hara. Mr O'Hara is recovering after a short illness
and expects to be back at work shortly.
Neil Davidson,
Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like
to thank Graham for his contribution to the Company over the last
year and welcome David as we move to our next stage of
growth."
|
For further
information, please contact: OptiBiotix Health
plc
|
www.optibiotix.com
|
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
|
Stephen O'Hara, Chief Executive
|
|
|
|
|
|
Cairn
Financial Advisers LLP (NOMAD)
|
Tel: 020 7213
0880
|
|
Liam Murray / Jo Turner / Ludovico
Lazzaretti
|
|
|
|
|
|
Peterhouse
Capital Limited (Broker)
|
Tel: 020 7220
9797
|
|
Duncan Vasey / Lucy Williams
|
|
|
|
|
|
Walbrook PR
Ltd
|
Mob: 07876 741
001
|
|
Anna Dunphy
|
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.